Generic Name and Formulations:
Potassium (as bicarbonate and citrate) 25mEq; effervescent tabs for soln; lime and orange flavor.
- Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women
- Postoperative Pulmonary Complications With Asthma or COPD
- Stable Hypercapnic COPD May Benefit From At-Home High-Flow Nasal Cannula Oxygen Therapy
- Do Not Crush or Chew
- Error-Prone Drug Name Abbreviations
- Beers List: Potentially Inappropriate Drugs for Elderly
Indications for K-LYTE:
Hypokalemia, including that caused by diuretics. Digitalis intoxication without AV block.
Prophylaxis: 25mEq daily. Treatment: 50–100mEq daily in divided doses. Both, dissolve each tab in 4–8oz of water and sip slowly over 5–10 minutes after meals.
Hyperkalemia. Chronic renal disease. Acute dehydration. Heat cramps. Severe tissue destruction. Adrenal insufficiency. Familial periodic paralysis. Acidosis (potassium chloride products). Alkalosis (potassium bicarbonate products). Tablets: Esophageal compression due to enlarged left atrium. Decreased GI motility.
Discontinue if GI bleed, ulceration, or other disturbances occur. Renal or cardiac disease. Monitor potassium level, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with ACE inhibitors, spironolactone, triamterene, amiloride, and potassium-containing salt substitutes. Anticholinergics, other agents that decrease GI motility increase risk of serious GI reactions with tablets.
Hyperkalemia, GI discomfort and irritation, diarrhea, rash (rare). Tablets: Esophageal and GI ulceration, bleeding, obstruction, perforation.
K-Lyte—30, 100, 250; DS—30, 100